EXECUTIVE SUMMARY REPORT

Pakistan Pharmaceutical Market

1st HALF 2010

The report is for the exclusive use of the recipient and may not be reproduced in any
form without the written consent from IMS. The information contained in the report is confidential and may not be divulged to any other party. Copyright IMS AG, ZUG Switzerland 2009

Executive Summary Report

Pharmaceutical Market

1st HALF 2010

The report is for the exclusive use of the recipient and may
not be reproduced in any form without the written consent from IMS. The information contained in the report is confidential and may not be divulged to any other party. Copyright IMS AG, ZUG Switzerland 2009

TABLE OF CONTENTS

Foreword by Dr. Aman Ullah Khan

04

World market Company news in Brief Global Pharmaceutical Sales

06 14

Pakistan Pharmaceutical Market Market Overview Multi-Vitamin Price Increase Analysis Commentary Tables

16 21 22 PK 1-9

Clients Feedback Form FORM

29

FOREWORD

We are once again proud to present you the year end Executive Summary report based on Q2 2010 with analysis of the Pakistan market. The importance of this report has been highlighted by our respective clients who have time and again requested for this year end report. IMS Health has always offered a unique solution to the Pharmaceutical industry through this report and has played an important role in delineating the industry trends. We would however, appreciate your valuable comments in the attached feedback form enabling us to further improve the quality and content of this report.

Yours Sincerely,

Dr. Aman Ullah Khan Chief Executive

Tel Off: 021-4315148 / 4383700 E-mail: akhan@pk.imshealth.com

WORLD MARKET

MARCH 2010 DEVELOPMENTS

COMPANY NEWS IN BRIEF

MERGERS & ACQUISITIONS NOVARTIS is to buy US-based ORIEL in a bid to boost its portfolio of generic respiratory drugs. VALEANT announced two acquisitions, of a privately-held OTC and generics company in Brazil, and VITAL SCIENCE, a Canadian OTC dermatology firm. ABBOTT and WOCKHARDT terminated their deal through which the US giant was due to purchase the Indian manufacturers nutrition business; Wockhardt was unable some of its debt restructuring issues with overseas lenders. Licensing WARNER CHILCOTT amended its Actonel collaboration with SANOFIAVENTIS (inherited with Procter & Gambles pharmaceutical unit) and will take full control of the osteoporosis drug in the US and Puerto Rico, while ATON acquired the US rights to BRISTOL-MYERS SQUIBBs Parkinsons therapy Lodosyn. TAKEDA licensed AMAGs Feraheme anaemia drug in many territories outside of the US, while MERCK & CO gained the rights to MASSBIOLOGICS tetanus-diphtheria vaccine in the US. FERRING will copromote XANODYNEs Zipsor NSAID in the US, INVIDA is to commercialise IPSENs specialty care drugs in South-east Asia, and ESTEVE will comarket RECORDATIs cholesterol therapy pitavastatin (licensed from KOWA) in Spain. Merck & Co is to co-promote NYCOMEDs COPD treatment Daxas in Canada and certain major EU countries, and will have exclusive commercialisation rights in the UK. ALLERGAN licensed SERENITYs Phase III compound for nocturia, Ser-120, while Novartis began a strategic oncology collaboration with ARRAY focusing on MEK inhibitors. sanofiaventis licensed CUREDMs experimental diabetes treatment Pancreate. GLAXOSMITHKLINE is to work with CRUCELL on a second-generation malaria vaccine, and PFIZER announced an alliance with MICURX and CUMENCOR focusing on antibiotics designed to tackle drug-resistant tuberculosis in China.

Regulatory activity Both the FDA and EMA cleared OSI and ROCHEs Tarceva for the additional indication of the maintenance therapy of advanced non-small cell lung cancer after platinum-based chemotherapy. In the EU, ASTRAZENECA and SHIONOGIs statin Crestor was approved for the prevention of major cardiovascular events in high-risk patients. The FDA approved PURDUEs reformulated version of the opioid analgesic OxyContin, designed to deter tampering and abuse. AstraZeneca and POZEN received a green light for their NSAID/PPI combination Vimovo, for arthritis patients at risk of developing NSAID-associated gastric ulcers. Also approved in the US were Novartis Zortress (Certican), for the prevention of organ rejection in adult kidney transplant recipients, and JOHNSON & JOHNSONs Pancreaze, an enzyme designed to aid digestion in patients with e.g. cystic fibrosis. The EMA cleared GENMAB and GSKs Arzerra, for the treatment of refractory chronic lymphocytic leukaemia, while Takedas DPP-4 inhibitor for Type II diabetes, Nesina, was approved in Japan and Canada licensed TEVA and PALADINs extended-cycle oral contraceptive Seasonique.

APRIL 2010 DEVELOPMENTS

COMPANY NEWS IN BRIEF

Mergers & Acquisitions ABBOTT is to boost its emerging market presence with the $2.12bn+ acquisition of PIRAMALs domestic Healthcare Solutions business a leader in the Indian branded generics market; it also began an alliance with ZYDUS CADILA to commercialise a portfolio of the latters products in 15 emerging markets and created a stand-alone Established Products Division. OSI accepted a higher, $4bn bid from ASTELLAS. ENDO is to acquire HEALTHTRONICS, a US provider of urological products and services, while VALEANT is buying ATON, which focuses on ophthalmology and orphan drugs. Licensing SANOFI-AVENTIS began a joint venture in Japan with NICHI-IKO, focusing on generics, and announced a licensing agreement with GLENMARK for the latters experimental chronic pain therapy, GRC 15300. SAGENT will market a portfolio of ACTAVIS specialty generic injectables in the US. TAKEDA is to co-promote its multiple myeloma therapy VELCADE in Japan with partner JOHNSON & JOHNSON, while FERRING acquired Lysteda, for heavy menstrual bleeding, for marketing in the US from XANODYNE and ZAMBON will co-market RECORDATIs BPH drug Silodyx in France. PFIZER is to acquire ERGONEXs terguride, in Phase II trials for pulmonary arterial hypertension, and also announced a "groundbreaking" collaboration with Washington University, which will focus on new uses for existing compounds. BOEHRINGER INGELHEIM began an alliance with MICROMET for an antibody against multiple myeloma, and ASTRAZENECA entered into a research agreement with the Global Alliance for TB Drug Development.

Regulatory activity The FDA approved: BAYERs novel oral contraceptive Natazia (known as Qlaira in Europe); GENZYMEs new Pompe disease therapy Lumizyme; ALLERGANs Zymaxid for bacterial conjunctivitis; and CIPHERs extendedrelease tramadol though its marketing hinges on the outcome of a patent dispute between PURDUE and PAR. The agency declined to approve DAINIPPON SUMITOMOs Stedesa as a treatment for epilepsy. The EMA cleared AMGENs Prolia for the treatment of post-menopausal osteoporosis in women at increased risk of fractures; GLAXOSMITHKLINE will be co-marketing the six-monthly injectable product in Europe. Canada approved NOVO NORDISKs Victoza for Type II diabetes and Valeants Onsolis, an opioid analgesic for breakthrough pain in cancer patients.

MAY 2010 DEVELOPMENTS

COMPANY NEWS IN BRIEF

Mergers & Acquisitions BIOVAIL and VALEANT announced a $3.3bn merger that will see the Canadian specialty firm buy its US peer; the new entity will be known as Valeant and run by the latters CEO (based in Barbados), but be domiciled in Canada. SANOFI-AVENTIS is to acquire TARGEGEN, which focuses on small molecule kinase inhibitors, for up to $560m; GLAXOSMITHKLINE bought Argentinas LABORATORIOS PHOENIX; GILEAD is to buy CGI, another kinase specialist; and JOHNSON & JOHNSON acquired RESPIVERT, a British developer of inhaled therapies for pulmonary diseases. Licensing MERCK & CO announced a strategic collaboration with ADCOCK INGRAM, which will distribute and co-promote a number of its products in South Africa. PERRIGO acquired the US rights to TEVAs OTC versions of sanofiaventis Allegra and Allegra D-12 antihistamines, while BAUSCH & LOMB bought SIRIONs Zirgan, for herpetic keratitis. GSK will market MEDIVIRs OTC cold sore treatment Xerclear in Europe, Japan, India and Australasia; TALECRIS and NOVARTIS will co-promote each others post-exposure rabies products; SIGMA-TAU is to commercialise DYAXs ecallantide for hereditary angioedema in Europe, Russia, North Africa and the Middle East; and ALMIRALL will distribute BASILEAs eczema therapy Toctino in Mexico and selected European markets. METABOLEX announced diabetes collaborations with both sanofi-aventis (GPR119 modulators) and J&J, while the latter also began a deal for DIAMYDs Phase III GAD65 antigen-based therapy for Type I diabetes. ABBOTT licensed NEUROCRINEs elagolix, for endometriosis, and Neurocrine also began a GPR119 agonist collaboration for Type II diabetes with BOEHRINGER INGELHEIM. Biovail licensed KYOWA HAKKO KIRINs istradefylline, for Parkinsons disease, in the US and Canada, while HELSINN extended its collaboration with EISAI to include the development of a fixed-dose combination anti-emetic for the US market. GSK will market LABTECs topical cold sore patch; AESTUS gained worldwide rights to ASTELLAS FK614, for neuropathic pain; Boehringer Ingelheim licensed MARINOMEDs antiviral nasal spray; and LILLY will commercialise MARCADIAs short-acting glucagon analogues for severe hypoglycaemia. 10

Sanofi-aventis began a major alliance with REGULUS for microRNA therapeutics for fibrosis, an HDM2/p53 cancer collaboration with ASCENTA, and an agreement with VIVALIS covering human monoclonal antibodies against infectious diseases. BAYER is to work with ONCOMED on stem cell therapeutics for cancer and TAURX on Alzheimers disease diagnostics and management tools. TAKEDA is to resume the production of flu vaccines using technology from BAXTER. FOREST will commercialise glucokinase activators from TRANSTECH for the treatment of diabetes; NYCOMED began a pain drug discovery collaboration with ESSEN; and ORASI will assist LUNDBECK with its development of CNS disorder compounds. BRISTOL-MYERS SQUIBB returned the rights to EXELIXIS XL184, a MET inhibitor in clinical trials for various tumour types, after the two companies were unable to agree on the appropriate clinical programme. Regulatory activity In the US, KOWA and Lilly launched statin Livalo; FERRING began marketing Lysteda, for cyclic heavy menstrual bleeding; and Takeda introduced ACTOplus met for Type II diabetes. The FDA granted additional indications to Novartis Tasigna (newlydiagnosed Ph+ chronic myeloid leukaemia) and ROCHEs Lucentis (macular oedema following retinal vein occlusion). New approvals were issued for AMGENs Prolia, as a treatment for post-menopausal women with osteoporosis at high risk of fracture; Merck & Cos Dulera for asthma in patients aged 12+; sanofi-aventis Jevtana for metastatic hormonerefractory prostate cancer previously treated with a docetaxel-containing regimen; GSKs Jalyn for benign prostatic hyperplasia; and Forest and MERZs Namenda XR for moderate-to-severe Alzheimers. The agency informed HUMAN GENOME SCIENCES and Novartis that it was unlikely to approve Zalbin for chronic hepatitis C using the dosing regimen outlined in the BLA. In the EU, GSK secured conditional approval for its renal cell carcinoma therapy Votrient, and the UK cleared GW PHARMACEUTICALS and Bayers Sativex, a cannabis-based product for the treatment of spasticity due to multiple sclerosis.

11

JUNE 2010 DEVELOPMENTS

COMPANY NEWS IN BRIEF

Mergers & Acquisitions SANOFI-AVENTIS was rumoured to be considering a $20bn deal in the US, and speculation soon began to focus on troubled GENZYME. Later the French giant was said to have made an informal approach to the US biotech, which has been plagued by manufacturing problems; GLAXOSMITHKLINE was also reported to have made similar contact. MYLAN is to acquire BIONICHE, a global manufacturer of injectable pharmaceuticals, while LILLY is buying ALNARA, which develops protein therapeutics for metabolic diseases such as cystic fibrosis. APTUIT is to purchase GSKs research operations in Italy, and PFIZER divested its Idun apoptosis R&D subsidiary to CONATUS, which is led by Iduns former CEO. Licensing MERCK & CO signed a statement of mutual intent with SINOPHARM, which will initially focus on promoting Gardasil and other Merck vaccines in China. EISAI is to commercialise ARENAs obesity drug lorcaserin in the US and also began a collaboration with AESTUS for the development of novel psychiatric therapeutics. GSK exercised its option to develop ANACORs antibiotic AN3365; ROCHE licensed NOVIMMUNEs anti-IL17 MAb, for autoimmune disorders; WATSON is to develop ITEROs recombinant follicle stimulating hormone, a biosimilar for female infertility; and BIOGEN IDEC licensed AMORFIXs lead amyotrophic lateral sclerosis MAbs. SERVIER and GALAPAGOS announced a strategic alliance to develop novel small molecules for osteoarthritis. ACTIENT acquired six specialty pharmaceuticals from UCB, and LUNDBECK returned the US rights to GTC BIOTHERAPEUTICS ATryn, for hereditary antithrombin deficiency. MERCK KGaA licensed out EMD 670744, a Phase I cancer vaccine, to IMMUNOVACCINE. Regulatory activity The FDA approved SHIRE and NOVENs ADHD patch Daytrana for additional use in adolescents (ages 13-17). The EMA cleared BRISTOLMYERS SQUIBBs Orencia as a first-line biologic treatment after an inadequate response to a DMARD, in combination with methotrexate, in moderate-to-severe rheumatoid arthritis, while in the UK, ALLERGANs Botox was approved for the prophylaxis of headaches in 12

adults with chronic migraine. New products that passed regulatory review in the US included PURDUEs Butrans, an opioid analgesic patch for moderate-to-severe chronic pain; DAIICHI SANKYOs triple combination antihypertensive (second-line) Tribenzor; MONOSOL and PARs (Strativa) Zuplenza, an oral soluble film formulation of ondansetron for nausea and vomiting; and SHIONOGIs Cuvposa, for chronic severe drooling in paediatric patients with neurological conditions such as cerebral palsy. The EC cleared NYCOMEDs Daxas for COPD; it will be co-promoted by Merck & Co in some countries. Also approved were RECORDATIs statin Livazo, licensed from KOWA, and Allergans Ozurdex, for macular oedema. Russia became the first country to licence Merck KGaAs pill for multiple sclerosis, cladribine, while Japan cleared ABRAXIS and OTSUKAs Abraxane for breast cancer.

13

Sales through Retail Pharmacies (Twelve months to June 2010)

NORTH AMERICA $241.1 billion up 5%

U.S.A. $222.1 billion up 5% CANADA $19.0 billion up 7%

EUROPE (TOP 5) $110.6 billion up 2%

GERMANY $35.9 billion up 5% FRANCE $29.3 billion up 1% ITALY $16.5 billion up 1% SPAIN $15.1 billion up 3% UK $13.8 billion up 3%

JAPAN (including hospitals) $82.0 billion up 4% CHINA (hospital) $29.3 billion up 28% LATIN AMERICA (TOP 4) $32.7 billion

BRAZIL $15.7 billion up 19% MEXICO $7.5 billion up 1% VENEZUELA $5.9 billion up 29% ARGENTINA $3.6 billion up 22%

1. 2. 3. 4. 5.

AUSTRALIA/NZ $9 billion up 6% The top 5 therapy classes at ATC3 level in the 12 months to June 2010 were:
C10A Cholesterol & trigly. regulators A2B - Antiulcerants N6A Antidepressants & mood stabilisers N5A - Antipsychotics C9C Angioten-II Antag, Plain

1. 2. 3. 4. 5.

The top 5 products in the 12 months to June 2010 were:

Lipitor Plavix Nexium Seretide Crestor

1. 2. 3. 4. 5.

The top 5 corporations in the 12 months to June 2010 were:

Pfizer Novartis AstraZeneca Merck & Co GlaxoSmithKline

14

Pakistan Pharmaceutical Market

15

MARKET OVERVIEW

The 1st Half 2010 ended with double digit growth for both MNCs and NAT. With the market size 131.827 billions, the industry grew exceptionally well with the phenomenal positive growth of +15.35% in Q210. Nationals remain dominant with the growth of +16.74% while Multinationals also grew with a double digit growth of +13.80% (MAT Q2 basis).

MAT QTRLY GROWTH 2007 TO 2010

30.00
23.25 21.37 22.26 21.55 18.65

20.00
G ROWTH 13.45 +/- %
10.00 15.62 16.08 13.23 12.47 13.29 10.20

15.14 13.50 11.86 11.46 19.15 18.60 18.79 17.82 16.19

17.24

16.74 15.35

12.45

11.42

14.18 8.53

14.90 14.75

15.81

15.43

10.00
9.41 6.92 10.48 7.96 9.54

13.51 13.41

13.80

9.39

0.00
Q 1-07 Q 2-07 Q 3-07 Q 4-07 Q 1-08 Q 2-08 Q 3-08 Q 4-08 Q 1-09 Q 2-09 Q 3-09 Q 4-09 Q 1-10 Q 2-10

Total

NATIONAL

MULTI-NATIONAL

The race is on between the multinationals and nationals. Nationals are gaining on multinational capturing share of 53.50% leaving multinational behind. However Multinationals still dominate unit market share with 50.25% as compared to Nationals 49.75% (based on Q2 2010).

16

NEW PRODUCT LAUNCHES

The overall market dynamics are tilted in favor of national companies as they are continuously launching new products at a much faster rate than MNCs, a trend which is becoming increasingly evident. The value and total number of new products launched by the industry during Jan 2010 Jun 2010 are as follows; Value MULTI-NATIONAL NATIONAL TOTAL 67,111,217 423,199,175 490,310,392 Number of New Products 11 347

358

17

MULTINATIONAL VS NATIONAL ANALYSIS

At present, there are 27 major MNCs operating in the country with a share of almost 46.50% in value. A historical comparison of MNCs share analysis over the last five years is shown in the chart below. The graph shows a clear gradual decline in share of MNCs. MNCs have lost 4.50% in value while in units they have lost 2.82%.

53.50
2010

46.50 52.87

2009

47.13 51.29 48.71 50.36

2008

V AL UE %

2007

49.64 49

2006

51
5 15 25 35 45 55

M C N

N AT

2010

49.75 50.25 48.69

2009

51.31 47.72
2008

52.28 47.34

UNI T %

2007

52.66 46.93

2006

53.07
5 15 M C N 25 35 N AT 45 55

The evolution index of MNCs is 98.650 & NAT is 101.20 in the 1st Half of 2010.

18

DERIVED MARKET ANALYSIS

As market share analysis is one of the key yardsticks to measure performance, it would be more pertinent to analyze Corporates in their own competing grounds. As would be observed below, there are major shifts for some companies creating new ranking dimensions to corporate listings. The results are tabulated as under:

The operating marketing size of GlaxoSmithKline is the largest among the top 20 Corporates followed by Searle, Novartis, Highnoon, Abbott and Barrett Hodgson. Thus, on the basis of the above and according to redefined market shares, the top 10 corporate rankings in descending order would be: Nestle, GlaxoSmithKline, Roche, Abbott, Bayer, Pfizer, Getz, Novartis and Sanofi-Aventis. However, Nestle sales are mainly from their consumer (non- pharmaceutical) products.

19

ACTIVE MARKET
Fair deal of idea could be extracted from the following table, where the top 20 ATCs are analyzed under corporate contribution (Multinational & National), formulation and number of brands available.

Of the 20 TC analyzed the honors are nearly equally shared by MNC and Nationals as MNCs dominates in 9 ATCs while National dominate the rest 11.

20

Multi-Vitamin Price Increase Analysis

As we all know that MOH granted a limited price increase on certain categories of drugs i.e. Vitamin B complex (A11E) in the month of April 2010. IMS has analyzed the pre price increase situation of this segment and the post price increase behavior of the same. The price as we all know was granted to a total market of A11E in terms of units was 35.29 Mn as on (Jan 2010 MAT Basis). It is interesting to note that although the price increase took place from 1st April 2010 but the increase in sales already had taken place from March 2010 i.e., a month earlier.

The main beneficiaries of the price increase were mostly MNCs as they hold the major share in this segment. The analysis shows that the total market that was hardly growing -0.85% (Feb Vs Jan 2010) before March abruptly went up by 48 % (March Vs Feb 2010). However this was not sustained as following month slowed down the growth to 27% (April Vs March) and -25% (May Vs April) and it was -14% (June Vs May 2010). Hence the negative performance of this segment tailed off the huge growth we had observed in March and April.

21

MARKET COMMENTARY (MAT Q2 2010 Vs MAT Q2 2009)

LEADING 20 CORPORATES The overall market jumped to 131-billion rupee mark with a growth of +15.35% on MAT Q2 basis. The top 20 Corporates crossed the 1 billion mark, of these 10 are multinationals and 10 nationals respectively, the top 20 Corporates contribute 62.86%. GSK alone contributes 10.15% of the total market. The first three positions remained in the same hands those of GlaxoSmithKline, Abbott and Pfizer respectively. Novartis, Sanofi Aventis, Getz, Bayer and ICI retained their positions. In the top 20 slot Sami clinched the 7th position, whereas Bosch moved two positions up from 14th to 12th clinching Highnoons position, Searle moved three positions up from 11th to 8th position clinching Samis position, Nestle moved four positions up from 18th to 14th clinching Boschs position and Barrett Hodgson also moved up one position from 19th to 18th position clinching Nestle position. The Corporates managing to grow more than the market (having evolution indices above 100) are Abbott, Sanofi Aventis, Getz, Sami, Searle, Bosch, Highnoon, Nestle, Bayer and Barrett Hodgson. Amongst the top 20 Corporates, Nestle, was the fastest growing company (+50.20%) followed by Searle (+47.18%), Bosch (+38.75%), and Sami (+22.44%). LEADING 20 MULTINATIONAL CORPORATES Although the MNCs grew with double digit +13.80% they gained around .63% share in value to the national companies at MAT Q2 - 2010 as compared to MAT Q2 2009. Total market size of MNC moved from Rs. 53.86 Bn to Rs 61.29 Bn. The top 7 slots remained in the same hands while there were shifts in rankings in the following league of MNCs Club as Nestle moved two position up from 10th to 8th , Bayer one position down from 8th to 9th , BMS one position down from 9th to 10th , Chiesi one position up from 15th to 14th , Servier one position up from 16th to 15th and Stiefel two position down from 14th to 16th. The companies who have maintained their position are GSK, Abbott, Pfizer, Novartis, Sanofi Aventis, Roche, Merck, Johnson & Johnson, Eli Lilly, Reckitt Benckiser, Alcon, Novo Nordisk Schering Plough. The fastest growing corporate is Nestle with a growth of +50.20% followed by Abbott 24.05%, Novo Nordisk +23.98%, Sanofi Aventis +18.60%, and Alcon +16.32%.

22

LEADING 20 NATIONAL CORPORATES The national Corporates are consistently gaining share in the market, growing at +16.74%. The national market has a value of Rs. 70.53 billions with a share of 53.50%. In the top 10 slot Searle has clinched Hiltons position by moving up from 4th to 3rd, Bosch moving up from 7th to 5th, Barrett Hodgson moving up from 9th to 8th (clinched OBS position). The companies that maintained their position in the top 20s are: Getz, Sami, ICI, Indus, Nabiqasim, High-Q Intl, and Macter. Within the top 20 movement in slots in last one year MAT Q2 2010 Vs MAT Q2 2009 are as follows

Rank Movement S#
1 2 3 4 5 6 7 8 9 10 11 12 13 14

COMPANIES
Searle Hilton Bosch AGP Highnoon AGP Barrett Hodgson OBS CCL Atco Geofman Ferozsons Platinum Global

From
4 3 7 5 5 6 9 8 13 12 27 14 15 25

To
3 4 5 7 6 7 8 9 12 13 14 15 19 20

Amongst the top 20 nationals, the fastest growing were Geofman (+72.42), Searle (+47.18), Bosch (+38.75%), Global (+32.44), CCL (+28.42%), Sami (+22.44), Atco (+21.52%), and Nabiqasim (+20.40%).

23

LEADING 20 ATCS All the leading top 20 ATCs (at 3rd level) have crossed the Rupees 1 billion mark. The top 4 ATCs remain the same however the ATCs that underwent rank movements are; Rank Movement From To
7 5 6 9 8 17 10 13 13 14 18 15 16 22 21 5 6 7 8 9 13 11 12 14 15 16 17 18 19 20

TCIII
V06C A02B N02B J01F B03A A11E N05C J05B N05C N03A N06A A10H C07A R05C C10A

DESCRIPTION
INFANT FORMULAS ANTIULCERANTS NON-NARCOTIC ANALGESICS MACROLIDES & SIMILAR TYPE HEAMATINICS, IRON & COMBS VITAMINS B COMPLEX TRANQULLIZERS ANTIVIRALS EXCL ANTI-HIV TRANQULLIZERS ANTI-EPILEPTICS ANTIDEPRESS. & MOOD STAB. SULPHONYLUREAS A-DIABS BETA BLOCKING AGENT PLAIN EXPECTORANTS CHOLEST&TRIGLY.REGULATOR

Among the top 20 ATCs, the fastest growing ATC were Infant formulas (+47.94%), followed by Vitamin B Complex (+29.11), Expectorants (+25.84%), Cholest & Triglycride Regulator (+18.64%), and AntiEpileptics (18.34%). All the ATCs had positive growth.

24

LEADING 20 PRODUCTS Augmentin is heading the leading top 20 products table, by a very big margin of 1.42 billion ahead of its next product with a growth of +14.19%. Again the Multinationals are leading the top 20 products list with 15 products against 5 products of Nationals. Among the leading 20 products, 7 products belong to GSK, 2 each products belong to Roche and Sami, while one product each belongs to Parke Davis, Bristol Myers Squibb, Sanofi-Aventis, Abbott, Nestle, Hilton, Getz, Eli Lilly , and Meiji. The top 20 products contribute 13.28% in the total market. Among the top 20 highest growth was seen in Meiji (+51.46%) followed by Lactogen (+42.26%), Panadol (+34.84), Oxidil (+24.57), Brufen (+24.38%), Pegasys( +21.55%), and Humulin 70/30 (+20.63). Besides the above out of the top 20, 17 products show double - digit growth this includes Augmentin, Amoxil, Velosef, Pegasys, Flagyl, Brufen, Lactogen, Meiji, Risek, Humulin 70/30, Rocephin, Novidat, Ampiclox, Panadol, and Ventolin. Among the leading 20 products, 8 belong to Anti-infective class, 4 to Alimentary Tract System, 2 to Infant Milk, 2 to Non Narcotic Analgesics, 1 each to Interferons, topical Corticosteroids, Antirheumatic topical and Anti Asthma.

LEADING 20 NEW PRODUCTS National Companies have a major dominance in the new product market (product < 25 months old) as 15 out of the top 20 belong to them. 3 products belonged to Sami, two products each belonged to Novartis, GSK, Getz and High-Q International. While one each to Meiji, Searle, LG LifeScience, Merck, Himont, Ferozsons, CCL, Global, and Almirall. Qalsan D is the leading product with a sales value of Rupees 123 millions and having 1.99% share from the total new products market. In terms of market share within new products, Meiji Big achieved 1.55%, followed by Rotec achieved 1.32% , and Infanrix Hexa (1.13%).

25

LEADING 20 SINGLE MOLECULES The single molecule market stood at Rs. 68.76 billion with a growth of +12.88%. All the leading top 20 Single molecules have crossed the Rupees 1 billion mark. Among the top 20 only Diclofenac, Ceftriaxone, Ciprofloxacin, Cefixime, Omeprazole, Amoxicillin and Montelukast maintained their ranks, while significant changes were seen in the ranking of the remaining molecules, further shown in the below table;

S.No
1 2 3 4 5 6 7 8 9 11 12 13 14 15

MOLECULES
PARACETAMOL CEFRADINE LEVOFLOXACIN MECOBALMIN LEVOFLOXACIN ESOMEPRAZOLE CLARTHROMYCIN METRONIDAZOLE IBUPROFEN CEFOTAXIME PEGINTERFERON ALFA-2A GLIMEPIRIDE MEFENAMIC ACID INTERFERON ALFA-2B

Rank Movement From To

8 7 10 9 10 19 15 14 16 13 17 18 11 12 7 8 9 10 9 11 12 13 14 15 16 17 18 19

Highest growth was seen in Esomeprazole (+37.65%), Paracetamol (+27.04), Metronidazole (+24.46%), Cefixime (+23.21%), Clarithromycin (+22.83%), and Peginterferon Alfa 2A (+21.55%).

26

L20 CORP

LEADING 20 CORPORATES
Valuewise in Pak Rupees
RANK Q2 Q2 2010 2009 CORPORATES TOTAL 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 1 2 3 4 5 6 8 11 7 9 10 14 12 18 15 13 16 19 17 20 GLAXOSMITHKLINE ABBOTT PFIZER NOVARTIS SANOFI-AVENTIS GETZ SAMI SEARLE ROCHE MERCK HILTON BOSCH HIGHNOON NESTLE BAYER AGP BRISTOL MYERS SQUI BARRETT HODGSON OBS I.C.I Others VALUE 131,827,642,331 13,385,426,849 7,991,008,226 6,606,922,473 5,835,091,994 5,273,855,967 4,903,159,859 4,148,441,689 3,962,671,613 3,944,647,272 3,490,097,342 3,430,695,024 2,853,204,068 2,488,579,411 2,463,555,066 2,332,359,915 2,217,143,774 2,024,625,057 1,903,008,127 1,892,923,916 1,714,810,013 48,965,414,676 MAT Q2 2010 GROWTH + % over Q2 2009 SHARE % 100.00 15.35 10.15 6.06 5.01 4.43 4.00 3.72 3.15 3.01 2.99 2.65 2.60 2.16 1.89 1.87 1.77 1.68 1.54 1.44 1.44 1.30 37.14 13.79 24.05 4.20 9.05 18.60 17.96 22.44 47.18 9.93 10.75 12.27 38.75 17.05 50.20 15.57 5.76 10.90 17.37 7.87 14.59 0.00 MAT Q2 2009 GROWTH + % over Q2 2008 SHARE % 100.00 18.60 10.29 5.64 5.55 4.68 3.89 3.64 2.96 2.36 3.14 2.76 2.67 1.80 1.86 1.44 1.77 1.83 1.60 1.42 1.54 1.31 37.85

EVOL 100.00 98.64 107.54 90.33 94.53 102.81 102.26 106.14 127.59 95.30 96.01 97.33 120.28 101.47 130.20 100.18 91.68 96.14 101.75 93.51 99.33 0.00

VALUE 114,280,703,492 11,763,279,746 6,441,795,628 6,340,652,459 5,351,079,663 4,446,742,915 4,156,601,200 3,388,079,613 2,692,386,931 3,588,324,433 3,151,378,740 3,055,794,253 2,056,430,761 2,125,999,830 1,640,219,835 2,018,206,023 2,096,379,660 1,825,635,848 1,621,339,245 1,754,781,399 1,496,534,563 43,269,060,747

EVOL 100.00 92.42 100.13 96.36 101.01 96.58 105.20 111.28 110.55 104.85 99.72 102.39 111.78 95.02 85.17 94.62 94.37 99.05 98.95 90.91 97.44 0.00

18.75 14.29 19.80 14.55 24.78 31.98 31.12 24.35 18.27 21.44 32.58 12.70 1.02 12.22 11.93 17.48 17.36 7.82 15.57 0.00

Pakistan Market

Page 1

LEADING 20 NATIONAL CORPORATES Q2 - 2010

Valuewise in Pak Rupees
RANK Q2 Q2 2010 2009 Total NATIONAL 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 1 2 4 3 7 5 6 9 8 10 11 13 12 27 14 16 17 18 15 25 GETZ SAMI SEARLE HILTON BOSCH HIGHNOON AGP BARRETT HODGSON OBS I.C.I INDUS CCL ATCO GEOFMAN FEROZSONS NABIQASIM HIGH-Q INTL MACTER PLATINUM GLOBAL Others MAT Q2 2010 GROWTH + SHARE % % over Q2 100.00 53.50 6.95 5.88 5.62 4.86 4.05 3.53 3.14 2.70 2.68 2.43 2.22 2.19 2.16 1.87 1.72 1.68 1.62 1.62 1.59 1.54 39.95 15.35 16.74 17.96 22.44 47.18 12.27 38.75 17.05 5.76 17.37 7.87 14.59 16.99 28.42 21.52 72.42 19.55 20.40 18.35 19.68 12.54 32.44 MAT Q2 2009 GROWTH + SHARE % % over Q2 100.00 52.87 6.88 5.61 4.46 5.06 3.40 3.52 3.47 2.68 2.90 2.48 2.22 1.99 2.07 1.27 1.68 1.63 1.60 1.58 1.65 1.35 42.50 18.60 22.26 24.78 31.98 31.12 21.44 32.58 12.70 11.93 17.36 7.82 15.57 34.73 34.50 34.67 27.64 16.01 9.07 33.84 12.10 23.11 2.31

CORPORATES

VALUE 131,827,635,902 70,530,169,769 4,903,159,859 4,148,441,689 3,962,671,613 3,430,695,024 2,853,204,068 2,488,579,411 2,217,143,774 1,903,008,127 1,892,923,916 1,714,810,013 1,568,936,950 1,541,516,428 1,523,281,560 1,321,371,317 1,216,157,556 1,183,948,228 1,145,118,766 1,142,667,985 1,123,453,582 1,083,361,700 28,165,718,203

EVOL 100.00 101.20 101.05 104.89 126.08 96.17 118.85 100.27 90.60 100.54 92.41 98.16 100.21 110.00 104.10 147.70 102.40 103.14 101.38 102.52 96.40 113.45

VALUE 114,280,703,342 60,417,419,376 4,156,601,200 3,388,079,613 2,692,386,931 3,055,794,253 2,056,430,761 2,125,999,830 2,096,379,660 1,621,339,245 1,754,781,399 1,496,534,563 1,341,129,291 1,200,412,359 1,253,488,224 766,376,353 1,017,320,568 983,334,060 967,587,515 954,799,074 998,276,268 818,021,632 25,672,346,577

EVOL 100.00 103.08 102.06 107.95 107.24 99.32 108.44 92.18 91.55 95.99 88.19 94.52 110.20 110.01 110.15 104.40 94.89 89.21 109.47 91.69 100.70 83.68

Pakistan Market

LEADING 20 MULTINATIONAL CORPORATES

Valuewise in Pak Rupees
RANK Q2 Q2 2010 2009 Total MULTI-NATIONAL 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 1 2 3 4 5 6 7 10 8 9 11 12 13 15 16 14 17 18 19 20 GLAXOSMITHKLINE ABBOTT PFIZER NOVARTIS SANOFI-AVENTIS ROCHE MERCK NESTLE BAYER BRISTOL MYERS SQUI JOHNSON & JOHNSON ELI LILLY RECKITT BENCKISER CHIESI FARMACEUTIC SERVIER STIEFEL OTSUKA ALCON NOVO NORDISK SCHERING PLOUGH Others CORPORATES MAT Q2 2010 GROWTH + % SHARE % over Q2 2009 100.00 15.35 46.50 21.84 13.04 10.78 9.52 8.60 6.44 5.69 4.02 3.80 3.30 2.44 2.06 1.55 1.30 1.26 1.23 1.06 0.61 0.61 0.52 0.33 13.80 13.79 24.05 4.20 9.05 18.60 9.93 10.75 50.20 15.57 10.90 13.26 14.81 7.36 9.68 15.68 -10.74 2.62 16.32 23.98 8.63 0.00 MAT Q2 2009 GROWTH + % SHARE % over Q2 2008 100.00 18.60 47.13 21.84 11.96 11.77 9.93 8.26 6.66 5.85 3.05 3.75 3.39 2.45 2.04 1.65 1.34 1.24 1.56 1.18 0.60 0.56 0.54 0.38 14.75 9.61 18.75 14.29 19.80 14.55 24.35 18.27 1.02 12.22 17.48 8.10 17.26 11.24 14.47 11.99 20.98 34.47 8.13 24.34 15.20 0.00

VALUE 131,827,635,902 61,297,472,562 13,385,426,849 7,991,008,226 6,606,922,473 5,835,091,994 5,273,855,967 3,944,647,272 3,490,097,342 2,463,555,066 2,332,359,915 2,024,625,057 1,492,618,271 1,259,756,220 952,189,381 794,433,614 771,017,383 751,125,175 652,746,194 375,285,463 374,247,287 315,798,739 210,664,674

EVOL 100.00 98.65 99.99 109.00 91.56 95.82 104.22 96.60 97.32 131.98 101.55 97.45 99.52 100.89 94.34 96.37 101.65 78.43 90.17 102.22 108.95 95.45 0.00

VALUE 114,280,703,342 53,863,284,116 11,763,279,746 6,441,795,628 6,340,652,459 5,351,079,663 4,446,742,915 3,588,324,433 3,151,378,740 1,640,219,835 2,018,206,023 1,825,635,848 1,317,887,339 1,097,207,600 886,913,768 724,344,199 666,508,721 841,521,078 636,077,920 322,620,162 301,854,498 290,714,924 210,318,617

EVOL 100.00 96.75 95.52 103.49 99.60 104.40 99.82 108.36 103.06 88.03 97.79 102.37 94.20 102.19 96.94 99.75 97.60 105.43 117.18 94.22 108.36 100.39 0.00

Pakistan Market

LEADING 20 THERAPEUTIC CLASSES

Valuewise in Pak Rupees
RANK Q2 Q2 2010 2009 TC III CODE THERAPEUTIC CLASS TOTAL 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 1 2 3 4 7 5 6 9 8 10 11 12 17 13 14 18 15 16 22 21 J01D M01A J01C J01G V06C A02B N02B J01F B03A A12A R06A J05B A11E N05C N03A N06A A10H C07A R05C C10A CEPHALOSPORINS & COMBS ANTIRHEUMATIC NON-STEROID BROAD SPECTRUM PENICILLIN FLUOROQUINOLONES INFANT FORMULAS ANTIULCERANTS NON-NARCOTIC ANALGESICS MACROLIDES & SIMILAR TYPE HAEMATINICS,IRON & COMBS CALCIUM ANTIHISTAMINES SYSTEMIC ANTIVIRALS EXCL ANTI-HIV VITAMIN B COMPLEX TRANQUILLIZERS ANTI-EPILEPTICS ANTIDEPRESS.& MOOD STAB. SULPHONYLUREA A-DIABS BETA BLOCKING AGENT PLAIN EXPECTORANTS CHOLEST&TRIGLY.REGULATOR Others VALUE 131,827,642,331 10,860,756,146 7,112,728,683 6,183,677,534 5,688,301,371 5,388,465,867 5,379,200,286 4,034,716,205 2,724,628,035 2,717,423,748 2,227,906,353 2,148,228,722 2,036,480,421 1,906,654,597 1,896,771,816 1,877,215,261 1,718,532,789 1,714,252,656 1,687,201,223 1,627,874,482 1,593,781,404 61,302,844,732 MAT Q2 2010 GROWTH + % over Q2 SHARE % 100.00 15.35 8.24 5.40 4.69 4.31 4.09 4.08 3.06 2.07 2.06 1.69 1.63 1.54 1.45 1.44 1.42 1.30 1.30 1.28 1.23 1.21 46.51 13.64 12.79 16.32 13.06 47.94 15.56 9.18 15.69 13.89 11.93 16.76 12.81 29.11 5.98 18.34 16.90 13.96 12.52 25.84 18.64 MAT Q2 2009 GROWTH + % over Q2 SHARE % 100.00 18.60 8.36 5.52 4.65 4.40 3.19 4.07 3.23 2.06 2.09 1.74 1.61 1.58 1.29 1.57 1.39 1.29 1.32 1.31 1.13 1.18 47.02 22.49 17.66 10.71 21.76 12.71 23.79 14.93 19.68 23.66 18.92 8.83 31.31 18.37 5.43 28.80 20.78 11.71 14.31 19.66 24.14

EVOL 100.00 98.52 97.77 100.83 98.01 128.25 100.18 94.64 100.29 98.73 97.03 101.22 97.79 111.92 91.87 102.59 101.34 98.79 97.54 109.09 102.84

VALUE 114,280,703,492 9,557,050,738 6,306,358,741 5,316,317,215 5,031,131,981 3,642,249,808 4,654,706,657 3,695,589,294 2,355,175,729 2,385,991,852 1,990,457,533 1,839,810,929 1,805,288,110 1,476,807,044 1,789,778,239 1,586,233,694 1,470,108,662 1,504,284,582 1,499,510,281 1,293,567,405 1,343,425,456 53,736,859,542

EVOL 100.00 103.28 99.20 93.35 102.66 95.03 104.37 96.90 100.91 104.26 100.26 91.76 110.71 99.81 88.89 108.59 101.83 94.19 96.38 100.89 104.67

Pakistan Market

LEADING 20 PRODUCTS
Valuewise in Pak Rupees
RANK Q2 Q2 2010 2009 TOTAL 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 1 2 4 5 6 7 3 13 19 9 8 14 10 12 15 23 17 18 20 26 AUGMENTIN AMOXIL VELOSEF PEGASYS FLAGYL BRUFEN PONSTAN LACTOGEN MEIJI MILK RISEK METHYCOBAL HUMULIN 70/30 ROCEPHIN NOVIDAT AMPICLOX PANADOL BETNOVATE N ZANTAC VENTOLIN OXIDIL Others GLAXOSMITHKLINE GLAXOSMITHKLINE BRISTOL MYERS SQUIB ROCHE SANOFI AVENTIS ABBOTT PARKE DAVIS NESTLE MEIJI GETZ EISAI ELI LILLY ROCHE SAMI GLAXOSMITHKLINE GLAXOSMITHKLINE GLAXOSMITHKLINE GLAXOSMITHKLINE GLAXOSMITHKLINE SAMI AMOXICILLIN / CLAVULANIC ACID AMOXICILLIN CEFRADINE PEGINTERFERON ALFA-2A METRONIDAZOLE IBUPROFEN MEFENAMIC ACID INFANT MILKS INFANT MILKS OMEPRAZOLE MECOBALAMIN INSULIN HUMAN BASE CEFTRIAXONE CIPROFLOXACIN AMPICILLIN / CLOXACILLIN PARACETAMOL BETAMETHASONE / NEOMYCIN RANITIDINE SALBUTAMOL CEFTRIAXONE J01C J01C J01D J05B J08B M02A N02B V06C V06C A02B A11F A10C J01D J01G J01C N02B D07B A02B R03A J01D MAT Q2 2010 PRODUCTS MANUFACTURER MOLECULE TC III VALUE 131,824,925,805 2,626,536,468 1,203,167,280 1,157,060,078 1,130,415,043 969,155,793 966,084,339 898,944,963 838,226,036 779,554,424 729,502,687 700,111,943 698,586,738 673,838,803 670,708,431 636,816,004 591,332,613 580,041,866 565,676,603 551,145,574 538,515,577 114,319,504,542 SHARE % GROWTH + % over Q2 2009 100.00 15.36 1.99 0.91 0.88 0.86 0.74 0.73 0.68 0.64 0.59 0.55 0.53 0.53 0.51 0.51 0.48 0.45 0.44 0.43 0.42 0.41 86.72 14.19 13.33 11.72 21.55 18.34 24.38 -14.42 42.26 51.46 18.90 5.73 20.63 11.53 13.50 10.21 34.84 7.57 9.16 8.79 24.57 EVOL 100.00 98.99 98.24 96.84 105.37 102.59 107.82 74.19 123.33 131.30 103.07 91.66 104.58 96.69 98.39 95.54 116.89 93.25 94.63 94.31 107.99 VALUE 114,276,539,016 2,300,221,157 1,061,680,408 1,035,711,853 930,023,252 818,927,987 776,726,355 1,050,446,222 589,204,753 514,687,796 613,564,410 662,167,355 579,097,316 604,150,499 590,936,435 577,796,990 438,553,348 539,226,566 518,192,503 506,610,824 432,303,221 99,136,309,766 MAT Q2 2009 SHARE % 100.00 2.01 0.93 0.91 0.81 0.72 0.68 0.92 0.52 0.45 0.54 0.58 0.51 0.53 0.52 0.51 0.38 0.47 0.45 0.44 0.38 86.74 GROWTH + % over Q2 2008 18.61 17.09 12.38 25.92 41.47 27.23 25.02 17.72 22.55 30.43 34.07 22.49 21.33 25.03 30.04 -9.78 0.18 13.35 13.36 8.10 50.44 EVOL 100.00 98.72 94.75 106.16 119.28 107.27 105.41 99.25 103.32 109.97 113.04 103.27 102.30 105.41 109.64 76.07 84.47 95.56 95.57 91.14 126.84

Pakistan Market

LEADING 20 MOLECULES
Valuewise in Pak Rupees
RANK Q2 Q2 2010 2009 TOTAL SINGLE MOLECULE TOTAL 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 1 2 3 4 5 6 8 7 10 9 19 15 14 16 13 17 18 11 12 20 DICLOFENAC CEFTRIAXONE CIPROFLOXACIN CEFIXIME OMEPRAZOLE AMOXICILLIN PARACETAMOL CEFRADINE LEVOFLOXACIN MECOBALAMIN ESOMEPRAZOLE CLARITHROMYCIN METRONIDAZOLE IBUPROFEN CEFOTAXIME PEGINTERFERON ALFA-2A GLIMEPIRIDE MEFENAMIC ACID INTERFERON ALFA-2B MONTELUKAST Others MAT Q2 2010 GROWTH + % SHARE % over Q2 2009 100.00 15.35 68.08 3.48 3.28 3.05 2.61 2.20 2.13 1.98 1.83 1.71 1.67 1.37 1.35 1.34 1.29 1.29 1.26 1.20 1.18 1.11 1.09 63.58 12.88 9.46 17.28 13.40 23.21 12.76 14.68 27.04 7.01 12.98 8.46 37.65 22.83 19.52 24.46 4.99 21.55 16.87 -13.83 -10.49 13.07 MAT Q2 2009 GROWTH + % SHARE % over Q2 2008 100.00 18.60 69.57 3.59 3.15 3.03 2.39 2.20 2.10 1.76 1.93 1.71 1.73 1.13 1.24 1.27 1.17 1.38 1.17 1.16 1.54 1.40 1.09 63.86 18.51 14.38 25.20 19.47 34.56 27.31 9.32 14.51 14.06 34.54 20.35 59.44 39.87 17.00 22.23 11.28 41.47 19.79 15.71 12.22 34.90

MOLECULE

VALUE 131,827,635,902 89,746,234,022 3,120,399,307 2,940,416,834 2,733,530,026 2,341,466,003 1,972,503,299 1,912,873,362 1,773,331,665 1,639,842,743 1,535,520,915 1,495,665,281 1,232,029,131 1,212,868,149 1,204,474,425 1,158,995,096 1,153,418,559 1,130,415,043 1,073,652,820 1,054,845,865 993,955,668 979,694,391 42,081,401,880

EVOL 100.00 97.86 96.97 103.90 100.46 109.14 99.89 101.60 112.54 94.80 100.09 96.08 121.94 108.81 105.88 110.26 93.00 107.68 103.54 76.33 79.30 100.16

VALUE 114,280,703,342 79,504,003,740 2,850,721,542 2,507,116,129 2,410,588,486 1,900,457,222 1,749,240,175 1,667,958,972 1,395,854,771 1,532,387,582 1,359,101,375 1,378,983,260 895,030,360 987,448,286 1,007,791,358 931,192,002 1,098,641,904 930,023,252 918,641,820 1,224,179,300 1,110,399,507 866,466,799 34,776,699,602

EVOL 100.00 99.92 96.52 105.65 100.82 113.55 107.43 92.25 96.63 96.25 113.53 101.56 134.54 118.03 98.73 103.14 93.90 119.38 101.08 97.64 94.70 113.83

Pakistan Market

LEADING 20 NEW PRODUCTS

Valuewise in Pak Rupees
RANK Q2 2010 PRODUCTS SELECTED TOTAL 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 QALSAN-D MEIJI BIG ROTEC INFANRIX HEXA IVF-C ESKEM ARCEVA POLYBION Z RITHMO EPITIZE CENTAURUS TASIGNA BISLERI-S TACAVIR REFRON TAMSOLIN CIDINE CIPVAL QUPRON INSUGET 70/30 Others NOVARTIS MEIJI SEARLE GLAXOSMITHKLINE LG LIFE SCIENCE HIGH Q INT'L SAMI MERCK SAMI HIMONT FEROZSONS NOVARTIS SAMI CCL GLOBAL GETZ ALMIRALL GLAXOSMITHKLINE HIGH Q INT'L GETZ COLECALCIFEROL / CALCIUM INFANT MILKS DICLOFENAC / MISOPROSTOL VACCINE, HEPATITIS B SURFACE ANTIGE CHORIONIC GONADOTROPHIN ESOMEPRAZOLE ARTEMETHER / LUMEFANTRINE ASCORBIC ACID / FOLIC ACID / VIT E CLARITHROMYCIN HERBAL ENTECAVIR NILOTINIB IRON METAL ENTECAVIR INTERFERON ALFA-2B TAMSULOSIN CINITAPRIDE CIPROFLOXACIN CIPROFLOXACIN INSULIN HUMAN BASE A12A V06C M01A J07B G03G A02B P01D A11E J01F A15A J05B L01X B03A J05B L03B G04C A03F J01G J01G A10C MANUFACTURER MOLECULE NAME ATC III MAT Q2 2010 VALUE SHARE % SHARE % IN ATC 6,202,267,521 100 123,135,965 96,025,454 82,091,400 70,160,922 65,350,951 65,134,782 62,254,716 61,192,811 61,063,005 57,687,082 55,333,216 54,987,520 51,747,176 51,592,453 45,243,636 41,104,676 39,589,229 39,323,521 38,103,180 38,029,746 5,797,627,088 1.99 1.55 1.32 1.13 1.05 1.05 1.00 0.99 0.98 0.93 0.89 0.89 0.83 0.83 0.73 0.66 0.64 0.63 0.61 0.61 80.70 5.52 1.78 1.15 56.35 12.55 1.21 4.53 3.20 2.24 8.13 2.71 8.92 1.90 2.53 4.19 11.45 2.80 0.69 0.66 2.69 MAT Q2 2009 VALUE SHARE % SHARE % IN ATC 1,765,883,693 100 0 34,968,695 27,536,524 40,819,976 0 20,765,037 22,033,785 28,428,951 30,651,101 34,181,933 8,203,860 90,440 22,144,207 8,092,000 2,867,729 13,488,176 6,801,889 0 0 9,094,086 1,455,715,304 0.00 1.98 1.56 2.31 0.00 1.18 1.25 1.61 1.74 1.94 0.46 0.01 1.25 0.46 0.16 0.76 0.39 0.00 0.00 0.51 82.43 0.00 0.96 0.44 56.49 0.00 0.45 1.85 1.93 1.30 5.39 0.45 0.02 0.93 0.45 0.23 4.83 0.53 0.00 0.00 0.71

Pakistan Market

MNC & NATIONAL SHARE IN PAKISTAN PHARMA MARKET (MAT 2Q , 2004-2010)

% SHARE IN VALUE
MARKET MULTI-NATIONAL NATIONAL 2004 55.14 44.86 2005 53.64 46.36 2006 51.00 49 2007 49.64 50.36 2008 48.71 51.29 2009 47.13 52.87 2010 46.50 53.5

% SHARE IN UNITS
MARKET MULTI-NATIONAL NATIONAL 2004 54.91 45.09 2005 54.53 45.47 2006 53.07 46.93 2007 52.66 47.34 2008 52.28 47.72 2009 51.31 48.69 2010 50.25 49.75

Pakistan Market

EXECUTIVE SUMMARY1ST HALF 2010

Feed back form Dear Client: We are pleased to present you the Executive Summary 1st Half 2010 report. Your valuable feedback on our earlier reports has helped us incorporate several new analyses in the subsequent reports. We request you to provide your feedback and rate the report on the following parameters. Parameter Content of the report Presentation style Value addition to your work Suggestions are most welcome Excellent Very Good Good Average Poor

Please address this page to Mr. A.G. Meghany and fax it back to us on 92-21-34314651 From: Name & Designation: Company: __________________________________ __________________________________

This report is for the exclusive use of IMS subscriber. No part of this report should be reported or reproduced without the prior written permission of IMS Switzerland.